Compare Inovio Pharmaceuticals Inc (INO) vs JetBlue Airways Corporation (JBLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs JetBlue Airways Corporation — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while JetBlue Airways Corporation trades at $5.34 (market cap $2.03B). The key difference: JetBlue Airways Corporation is far larger — about 22.7× Inovio Pharmaceuticals Inc's market cap, and JetBlue Airways Corporation is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | JBLU | |
|---|---|---|
Market Cap | $89.27M | $2.03B |
Sector | Health | Industrials |
52-Week High | $2.87 | $6.46 |
52-Week Low | $1.05 | $4.03 |
Enterprise Value | $60.28M | $9.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
JetBlue (JBLU) trades at $5.45, up 0.55% today, with technical indicators showing a neutral bias despite recent earnings misses. The airline reported a net loss of $602 million in 2025 with negative profit margins, though valuation metrics like P/S of 0.22 appear attractive. Recent news highlights expansion at Fort Lauderdale and new payment partnerships, while analyst consensus remains cautious with a $5.12 price target.
JBLU faces significant challenges with persistent losses and high debt levels, though strategic expansions and cost management efforts provide some optimism. The stock trades near analyst targets with mixed sentiment, requiring careful monitoring of upcoming Q2 2026 earnings and fuel cost trends for directional clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →
